Fuzeon Needle-Free Delivery System To Be Resubmitted To FDA In Second Half 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Growth for Roche/Trimeris' HIV fusion inhibitor is expected to be driven by the new system, which is currently "approvable" at FDA, and updated HHS treatment guidelines.